189 related articles for article (PubMed ID: 38164871)
1. Research trends of Janus Kinase inhibitors: a bibliometric and visualized study from 2012 to 2023.
Chang HC; Tsai RY; Lee CY; Kuan YH; Liao WC; Chen SJ; Gau SY
Eur Rev Med Pharmacol Sci; 2023 Dec; 27(24):12088-12102. PubMed ID: 38164871
[TBL] [Abstract][Full Text] [Related]
2. Research trends in alopecia areata: a cross-sectional bibliometric analysis of the top cited studies.
Chang HC; Chiu TM; Lee CY; Chen SJ; Liao WC; Gau SY
Arch Dermatol Res; 2024 May; 316(6):234. PubMed ID: 38795240
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
5. JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapies for atopic dermatitis: JAK inhibitors.
Cotter DG; Schairer D; Eichenfield L
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S53-S62. PubMed ID: 29248518
[TBL] [Abstract][Full Text] [Related]
7. Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs.
Zhao MY; Zhang W; Rao GW
Curr Med Chem; 2022 Aug; 29(29):5010-5040. PubMed ID: 35255783
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
9. A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders.
Kalantari Y; Sadeghi S; Asadi D; Goodarzi A
Int Immunopharmacol; 2022 Sep; 110():108923. PubMed ID: 35717838
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an
Frede N; Lorenzetti R; Hüppe JM; Janowska I; Troilo A; Schleyer MT; Venhoff AC; Voll RE; Thiel J; Venhoff N; Rizzi M
Front Immunol; 2023; 14():1087986. PubMed ID: 36776828
[TBL] [Abstract][Full Text] [Related]
11. JAK Inhibitors: Prospects in Connective Tissue Diseases.
You H; Xu D; Zhao J; Li J; Wang Q; Tian X; Li M; Zeng X
Clin Rev Allergy Immunol; 2020 Dec; 59(3):334-351. PubMed ID: 32222877
[TBL] [Abstract][Full Text] [Related]
12. Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients.
Tóth L; Juhász MF; Szabó L; Abada A; Kiss F; Hegyi P; Farkas N; Nagy G; Helyes Z
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163173
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
15. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
[TBL] [Abstract][Full Text] [Related]
16. [JAK inhibitors: Perspectives in internal medicine].
El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
Rev Med Interne; 2019 Dec; 40(12):816-825. PubMed ID: 31699450
[TBL] [Abstract][Full Text] [Related]
17. Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment.
Shih PY; Li CJ; Yong SB
Int Immunopharmacol; 2023 Nov; 124(Pt B):111029. PubMed ID: 37820425
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
Zhang L; Du D; Wang L; Guo L; Jiang X
J Dermatol; 2021 Dec; 48(12):1877-1883. PubMed ID: 34487567
[TBL] [Abstract][Full Text] [Related]
19. JAK inhibition in the treatment of inflammatory rheumatic diseases.
Šenolt L
Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
